The exponential advents of advances in techniques and types of molecular diagnostic testing, and modifying strategies for these tests, are encouraging; but these evolutions simultaneously continue to introduce challenges in clinical evaluations and subsequent medical policy and reimbursement decisions related to these events. Robust critiques and standardized analyses are always recommended for coverage decisions, but flexibilities may need to be considered when appropriate. ACCE & PICOTS Models etc. must drive any assessments before financial/economic capacities come into play.
1. Learning the criticality of evidence development, application, and evaluation
2. Introduction to & understanding of pivotal conceptual frameworks